Showing 21-30 of 353 grants

Title Institution Researcher Program Duration Total Award Amount
Combining Arteriovenous Bundle and ECM-Based Biomaterial Technologies to Induce Potent Neovascularization Following Islet Transplantation Wake Forest University Health Sciences Giuseppe Orlando Cures 01-April-2025 to 31-March-2027 $248.692,00
The master regulator transcription factor, Zbtb20, defines and controls a regulatory T cell subset that controls tissue inflammation Virginia Commonwealth University Derek Sant’Angelo Cures 01-September-2025 to 28-February-2027 $382.996,65
Accelerating the Identification and Mitigation of Insulin Pump Risks using Artificial Intelligence Veterans Health Foundation Ronald Codario Improving Lives 01-August-2026 to 31-July-2027 $189.038,48
Developing Fit-For-Purpose Patient-reported Outcomes (PRO) Measure(s) in Type 1 Diabetes Vector Psychometric Group R. J. Wirth Cures 01-February-2025 to 30-June-2027 $836.157,00
Determination of autoreactive B lymphocyte development by ROS in T1D Vanderbilt University Medical Center (VUMC) Christopher Wilson Cures 01-July-2023 to 30-June-2026 $211.157,03
B cell-Treg interactions in immune therapy for T1D Vanderbilt University Medical Center (VUMC) Daniel Moore Cures 01-March-2026 to 28-February-2029 $660.000,00
Bcl6 and the B/Tfh axis in type 1 diabetes pathogenesis Vanderbilt University Medical Center (VUMC) Dudley McNitt Cures 01-March-2024 to 28-February-2027 $264.964,50
Investigation of AKS-107 immunotherapeutic in mice and human cells Vanderbilt University Medical Center (VUMC) Rachel Bonami Cures 01-July-2024 to 30-June-2027 $800.000,00
Targeting the Autoimmune Germinal Center Axis in Type 1 Diabetes Vanderbilt University Medical Center (VUMC) Rachel Bonami Cures 01-March-2026 to 29-February-2028 $600.000,00
Targeting the CERS2-Sphingolipid Axis to Protect Human Beta-Cells in T1D Vanderbilt University Katie Coate Cures 01-May-2026 to 30-April-2027 $199.979,61